Remarkably, VPRBP inhibition combined with anti-PD-1 treatment dramatically retarded tumor growth in all immunocompetent Balb/c mice tested (11 of 11 mice; Fig. 4e, panel IV). This evidence concerns the gene DCAF1 and neoplasm.